Original PaperVascular endothelial growth factor is implicated in early invasion in cervical cancer
Introduction
Angiogenesis, the development of new blood vessels, is essential in tissue development, reproduction and wound healing[1]. Solid tumours require angiogenesis for progression and metastasis. In fact, tumour growth beyond 1–2 mm is strictly dependent on angiogenesis[2]. Angiogenesis also contributes to the metastatic process, carrying cancer cells into the circulation[3].
Tumour tissues secrete angiogenic factors that activate neovascularisation around tumours[1]. Vascular endothelial growth factor (VEGF) was originally detected in the conditioned medium of bovine pituitary folliculostellate cells. Vascular permeability factor (VPF) was identified in tumour ascites and was found to be identical to VEGF4, 5. VEGF is detectable in a number of tumour cell lines and tumour tissues and is thought to be a selective growth factor for endothelial cells[6]. Four molecular isoforms of VEGF are generated by alternative splicing, rendering proteins containing 206-, 189-, 165- and 121-amino acid residues[7]. The two shorter isoforms, VEGF165 and VEGF121, are secreted proteins which may act as diffusible agents, whereas the longer isoforms remain cell associated8, 9.
Recently, it was reported that microvessel density correlates with immunoreactivity of VEGF in stages Ib—IIb cervical cancer[10]. There has been no study investigating the level of VEGF mRNA in invasive cervical cancer. The present study examines both the expression of VEGF mRNA in stage Ia–IVb invasive cervical cancer tissues by semiquantitative reverse transcription–polymerase chain reaction (RT-PCR) and its association with clinicopathological features including microvessel density.
Section snippets
Tissue samples
The patient population consisted of 66 patients with a diagnosis of invasive cervical cancer at the Department of Obstetrics and Gynecology of Okayama University Medical School, Okayama, Japan, who underwent treatment from 1995 to 1996. Biopsy specimens obtained by colposcopy were available at the time of admission and each specimen was bisected. One portion was snap frozen and stored at −80°C until RNA was extracted. The other portion was fixed in 10% formaldehyde solution for
VEGF mRNA expression and clinicopathological features
Although VEGF 206 transcripts were not amplified, VEGF 189, 165 and 121 were routinely detected in this series of cervical cancer. The VEGF/β-actin (V/A) ratios ranged from 0.6 to 9.7, with an average of 3.9±2.6. Fig. 1 shows a representative final RT-PCR product for VEGF and β-actin and the corresponding values of the V/A ratios. The highest expression of VEGF mRNA was observed in early invasive cervical cancer. The stage of disease correlated significantly with a decrease in the V/A ratio,
Discussion
Several angiogenic factors have been described, such as acidic and basic fibroblast growth factor (bFGF), transforming growth factor-α (TGF-α), transforming growth factor-β, VEGF, placenta growth factor (PlGF), interleukin-8, tumour necrosis factor-α and platelet-derived endothelial cell growth factor/thymidine phosphorylase14, 15, 16, 17, 18. In invasive cervical cancer, the association between the expression of the most important angiogenic factor, VEGF, and clinicopathological factors
Acknowledgements
This work was partially supported in part by Grants-in-Aid for Scientific Research (09771277 and 09671684) from the Ministry of Education, Sport, Science and Culture, Japan. We thank Drs A. Dusso and T. Pavlopoulos for their assistance in the preparation of the manuscript.
References (38)
- et al.
Angiogenesis
J. Biol. Chem.
(1992) - et al.
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
Biochem. Biophys. Res. Commun.
(1989) - et al.
Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells
Methods Enzymol.
(1991) - et al.
Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor)
Biochem. Biophys. Res. Commun.
(1991) - et al.
Different angiogenic pathways in human cervical cancers
Gynecol. Oncol.
(1998) - et al.
Reverse correlation between P-glycoprotein expression and proliferative activity in endometrial adenocarcinoma
Eur. J. Obstet. Gynecol. Reprod. Biol.
(1995) - et al.
The implications of angiogenesis for the biology and therapy of cancer metastasis
Cell
(1994) - et al.
Relation of neovascularization to metastasis of non-small cell lung cancer
Lancet
(1992) - et al.
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer
Lancet
(1992) - et al.
Tumor angiogenesis: an independent prognostic parameter in cervical cancer
Am. J. Obstet. Gynecol.
(1996)
Tumor angiogenesis as a predictor of recurrence in stage Ib squamous cell carcinoma of the cervix
Obstet. Gynecol.
Tumor angiogenesis as a prognostic factor in cervical carcinoma
Gynecol. Oncol.
Tumor vascularity—a novel prognostic factor in advanced cervical carcinoma
Gynecol. Oncol.
Angiogenesis in cervical neoplasia: microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations
Gynecol. Oncol.
Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival
Am. J. Obstet. Gynecol.
What is the evidence that tumours are angiogenesis-dependent?
J. Natl. Cancer Inst.
Quantitative relationships of intravascular tumor cells, tumor vessel, and pulmonary metastases following tumour implantation
Cancer Res.
Tumor cells secret a vascular permeability factor that promotes accumulation of ascites fluid
Science
Molecular and biological properties of the vascular endothelial growth factor family of proteins
Endocr. Rev.
Cited by (78)
Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy
2020, Gynecologic OncologyCitation Excerpt :The amounts of TILs in intratumoral lesions may affect both the response to initial treatment and ultimate prognosis after treatment. Some angiogenesis factors in cervical cancer invasion, such as vascular endothelial growth factor (VEGF) [32], which is correlated with TILs in several types of human tumors [33,34], may also be involved in this study. In a future study, we will attempt to determine which factors are associated with T cell infiltration in cervical cancer.
Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer
2014, International Journal of Biochemistry and Cell BiologyTreatment of metastatic cervical cancer: Future directions involving targeted agents
2013, Critical Reviews in Oncology/HematologyCitation Excerpt :A summary of the clinical studies with antiangiogenic agents reported to date in metastatic cervical cancer can be found in Table 2. Angiogenesis plays a significant role in tumor progression from a premalignant lesion to an invasive cervical cancer [15,18–20]. Analysis of human cervical cancer specimens for VEGF mRNA expression and immunohistochemistry shows that VEGF is markedly up-regulated in human squamous carcinoma cells [20].
VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival
2010, Gynecologic OncologyCitation Excerpt :In the process of tumor angiogenesis, VEGF plays a pivotal role in endothelial cell survival, mitogenesis, migration, differentiation, vascular permeability, and mobilization of endothelial progenitor cells [5]. Expression of VEGF has been associated with increased microvessel density (MVD), tumor progression, and poor prognosis for various solid tumors, including cervical cancer [6–9]. In addition, increasing evidence suggests that HPV oncoproteins may enhance tumor angiogenesis via increased VEGF expression in cervical cancer [10,11].
Construction of a Six-Gene Prognostic Risk Model Related to Hypoxia and Angiogenesis for Cervical Cancer
2022, Frontiers in Genetics